These results suggest that despite the fact that NF-κB is involved in the control of over 150 target genes (Pahl, 1999), inhibitors of NF-κB activation do not produce overt toxicity and should be evaluated for the treatment of muscle atrophy in cancer cachexia. The gene discussed is NFKB1; the disease is cancer.